Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its dual role in promoting tumor cell migration and shaping a protective tumor microenvironment.
Jay Lalezari, PhD
Advertisement
Articles by Jay Lalezari, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer’s Proven Playbook: Buy, Partner, Scale, Spin-Off, Optimize
2
FDA Announces New Plausible Mechanism Pathway
3
Roundup: Ovid Therapeutics and Metagenomi Announce 2025 Third Quarter Results and Leadership Updates
4
WeightWatchers to Offer Novo Nordisk’s Oral Wegovy, if Approved Next Year
5
